Abstract
Sensitive to the massive diffusion of purported metabolic and cardiovascular positive effects of green tea and catechincontaining extracts, many consumers of cardiovascular drugs assume these products as a “natural” and presumably innocuous adjunctive way to increase their overall health. However, green tea may interfere with the oral bioavailability or activity of cardiovascular drugs by various mechanisms, potentially leading to reduced drug efficacy or increased drug toxicity. Available data about interactions between green tea and cardiovascular drugs in humans, updated in this review, are limited so far to warfarin, simvastatin and nadolol, and suggest that the average effects are mild to modest. Nevertheless, in cases of unexpected drug response or intolerance, it is warranted to consider a possible green tea-drug interaction, especially in people who assume large volumes of green tea and/or catechin-enriched products with the conviction that “more-is-better”.
Keywords: Green tea, herb-drug interaction, dietary-drug interaction, catechins, simvastatin, warfarin, nadolol, cardiovascular drugs.
Current Pharmaceutical Design
Title:Overview of Green Tea Interaction with Cardiovascular Drugs
Volume: 21 Issue: 9
Author(s): Jose P. Werba, Shingen Misaka, Monica G. Giroli, Shizuo Yamada, Viviana Cavalca, Keisuke Kawabe, Isabella Squellerio, Federica Laguzzi, Satomi Onoue, Fabrizio Veglia, Veronika Myasoedova, Kazuhiko Takeuchi, Eisuke Adachi, Naoki Inui, Elena Tremoli and Hiroshi Watanabe
Affiliation:
Keywords: Green tea, herb-drug interaction, dietary-drug interaction, catechins, simvastatin, warfarin, nadolol, cardiovascular drugs.
Abstract: Sensitive to the massive diffusion of purported metabolic and cardiovascular positive effects of green tea and catechincontaining extracts, many consumers of cardiovascular drugs assume these products as a “natural” and presumably innocuous adjunctive way to increase their overall health. However, green tea may interfere with the oral bioavailability or activity of cardiovascular drugs by various mechanisms, potentially leading to reduced drug efficacy or increased drug toxicity. Available data about interactions between green tea and cardiovascular drugs in humans, updated in this review, are limited so far to warfarin, simvastatin and nadolol, and suggest that the average effects are mild to modest. Nevertheless, in cases of unexpected drug response or intolerance, it is warranted to consider a possible green tea-drug interaction, especially in people who assume large volumes of green tea and/or catechin-enriched products with the conviction that “more-is-better”.
Export Options
About this article
Cite this article as:
Werba P. Jose, Misaka Shingen, Giroli G. Monica, Yamada Shizuo, Cavalca Viviana, Kawabe Keisuke, Squellerio Isabella, Laguzzi Federica, Onoue Satomi, Veglia Fabrizio, Myasoedova Veronika, Takeuchi Kazuhiko, Adachi Eisuke, Inui Naoki, Tremoli Elena and Watanabe Hiroshi, Overview of Green Tea Interaction with Cardiovascular Drugs, Current Pharmaceutical Design 2015; 21 (9) . https://dx.doi.org/10.2174/1381612820666141013135045
DOI https://dx.doi.org/10.2174/1381612820666141013135045 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
Advances in the Molecular Pathogenesis of Inflammatory Bowel Disease.
This thematic issue will emphasize the recent breakthroughs in the mechanisms of Inflammatory bowel disease (IBD) pathogenesis and devotes some understanding of both Crohn’s and ulcerative colitis. It is expected to include studies about cellular and genetic aspects, which help to precipitate the disease, and the immune system-gut microbiome relations ...read more
Blood-based biomarkers in large-scale screening for neurodegenerative diseases
Disease biomarkers are necessary tools that can be employ in several clinical context of use (COU), ranging from the (early) diagnosis, prognosis, prediction, to monitor of disease state and/or drug efficacy. Regarding neurodegenerative diseases, in particular Alzheimer’s disease (AD), a battery of well-validated biomarkers are available, such as cerebrospinal fluid ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Diabetes mellitus: advances in diagnosis and treatment driving by precision medicine
Diabetes mellitus (DM) is a chronic degenerative metabolic disease with ever increasing prevalence worldwide which is now an epidemic disease affecting 500 million people worldwide. Insufficient insulin secretion from pancreatic β cells unable to maintain blood glucose homeostasis is the main feature of this disease. Multifactorial and complex nature of ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Therapeutic Potential of Voltage Gated Calcium Channels
Mini-Reviews in Medicinal Chemistry Poor Safety and Tolerability Hamper Reaching a Potentially Therapeutic Dose in the Use of Thalidomide for Alzheimer’s Disease: Results from a Double-Blind, Placebo-Controlled Trial
Current Alzheimer Research Utility of Molecular Imaging with 2-Deoxy-2-[Fluorine-18] Fluoro-D-Glucose Positron Emission Tomography (18F-FDG PET) for Small Cell Lung Cancer (SCLC): A Radiation Oncology Perspective
Current Radiopharmaceuticals Low Density Lipoprotein Receptor-Related Proteins (LRPs), Alzheimers and Cognition
Current Drug Targets - CNS & Neurological Disorders Adrenomedullin in the Kidney-Renal Physiological and Pathophysiological Roles
Current Medicinal Chemistry Antiplatelet Therapy and Oral Anticoagulation for Prevention of Ischemic Stroke
Current Drug Therapy Small Molecule Inhibitors of PKCθ as Potential Antiinflammatory Therapeutics
Current Topics in Medicinal Chemistry Effect of Dietary Supplementation of Black Seed (N. Sativa L.) on Lipid Profile of Patients Suffering from Diabetes
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Migraine: Pathophysiology, Pharmacology, Treatment and Future Trends
Current Vascular Pharmacology Is Targeting microRNAs the Philosopher’s Stone for Vascular Disease?
Current Vascular Pharmacology Experimental Rodent Models of Vascular Dementia: A Systematic Review
CNS & Neurological Disorders - Drug Targets Development of an Efficient, Non-Invasive Method for Cardiovascular Disease Risk Stratification in a Resource-Limited Setting
Current Aging Science Long Noncoding RNA OIP5-AS1 Overexpression Promotes Viability and Inhibits High Glucose-Induced Oxidative Stress of Cardiomyocytes by Targeting MicroRNA-34a/SIRT1 Axis in Diabetic Cardiomyopathy
Endocrine, Metabolic & Immune Disorders - Drug Targets COVID-19 Infection in Hemodialysis Patients, Incidence, Risk Factors and Mortality. Single Centre Study
New Emirates Medical Journal Cholesteryl Ester Transfer Protein (CETP) Variations in Relation to Lipid Profiles and Cardiovascular Diseases: An Update
Current Pharmaceutical Design Optimal Medical Therapy for Coronary Artery Disease in 2011 – Perspectives from the STICH Trial
Cardiovascular & Hematological Agents in Medicinal Chemistry The Melanocortin Receptor System: A Target for Multiple Degenerative Diseases
Current Protein & Peptide Science Current and Future Perspectives on the Major Depressive Disorder: Focus on the New Multimodal Antidepressant Vortioxetine
CNS & Neurological Disorders - Drug Targets Vitamin D and Infectious Diseases
Endocrine, Metabolic & Immune Disorders - Drug Targets The IL-17 Family of Cytokines - Applications in Respiratory Medicine and Allergology
Recent Patents on Inflammation & Allergy Drug Discovery